These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 33436526)

  • 1. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.
    Koenig PA; Das H; Liu H; Kümmerer BM; Gohr FN; Jenster LM; Schiffelers LDJ; Tesfamariam YM; Uchima M; Wuerth JD; Gatterdam K; Ruetalo N; Christensen MH; Fandrey CI; Normann S; Tödtmann JMP; Pritzl S; Hanke L; Boos J; Yuan M; Zhu X; Schmid-Burgk JL; Kato H; Schindler M; Wilson IA; Geyer M; Ludwig KU; Hällberg BM; Wu NC; Schmidt FI
    Science; 2021 Feb; 371(6530):. PubMed ID: 33436526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants.
    Yuan M; Huang D; Lee CD; Wu NC; Jackson AM; Zhu X; Liu H; Peng L; van Gils MJ; Sanders RW; Burton DR; Reincke SM; Prüss H; Kreye J; Nemazee D; Ward AB; Wilson IA
    Science; 2021 Aug; 373(6556):818-823. PubMed ID: 34016740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.
    Starr TN; Greaney AJ; Addetia A; Hannon WW; Choudhary MC; Dingens AS; Li JZ; Bloom JD
    Science; 2021 Feb; 371(6531):850-854. PubMed ID: 33495308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
    Meng B; Abdullahi A; Ferreira IATM; Goonawardane N; Saito A; Kimura I; Yamasoba D; Gerber PP; Fatihi S; Rathore S; Zepeda SK; Papa G; Kemp SA; Ikeda T; Toyoda M; Tan TS; Kuramochi J; Mitsunaga S; Ueno T; Shirakawa K; Takaori-Kondo A; Brevini T; Mallery DL; Charles OJ; ; ; ; Bowen JE; Joshi A; Walls AC; Jackson L; Martin D; Smith KGC; Bradley J; Briggs JAG; Choi J; Madissoon E; Meyer KB; Mlcochova P; Ceron-Gutierrez L; Doffinger R; Teichmann SA; Fisher AJ; Pizzuto MS; de Marco A; Corti D; Hosmillo M; Lee JH; James LC; Thukral L; Veesler D; Sigal A; Sampaziotis F; Goodfellow IG; Matheson NJ; Sato K; Gupta RK
    Nature; 2022 Mar; 603(7902):706-714. PubMed ID: 35104837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies.
    Greaney AJ; Loes AN; Crawford KHD; Starr TN; Malone KD; Chu HY; Bloom JD
    Cell Host Microbe; 2021 Mar; 29(3):463-476.e6. PubMed ID: 33592168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination.
    Wang M; Zhang L; Li Q; Wang B; Liang Z; Sun Y; Nie J; Wu J; Su X; Qu X; Li Y; Wang Y; Huang W
    Emerg Microbes Infect; 2022 Dec; 11(1):18-29. PubMed ID: 34818119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo.
    Tsugawa Y; Furukawa K; Ise T; Takayama M; Ota T; Kuroda T; Shano S; Hashimoto T; Konishi H; Ishihara T; Sato M; Kamada H; Fukao K; Shishido T; Yoshikawa M; Takahashi T; Nagata S
    PLoS One; 2024; 19(12):e0300297. PubMed ID: 39621673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition.
    Greaney AJ; Starr TN; Gilchuk P; Zost SJ; Binshtein E; Loes AN; Hilton SK; Huddleston J; Eguia R; Crawford KHD; Dingens AS; Nargi RS; Sutton RE; Suryadevara N; Rothlauf PW; Liu Z; Whelan SPJ; Carnahan RH; Crowe JE; Bloom JD
    Cell Host Microbe; 2021 Jan; 29(1):44-57.e9. PubMed ID: 33259788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape.
    Starr TN; Czudnochowski N; Liu Z; Zatta F; Park YJ; Addetia A; Pinto D; Beltramello M; Hernandez P; Greaney AJ; Marzi R; Glass WG; Zhang I; Dingens AS; Bowen JE; Tortorici MA; Walls AC; Wojcechowskyj JA; De Marco A; Rosen LE; Zhou J; Montiel-Ruiz M; Kaiser H; Dillen JR; Tucker H; Bassi J; Silacci-Fregni C; Housley MP; di Iulio J; Lombardo G; Agostini M; Sprugasci N; Culap K; Jaconi S; Meury M; Dellota E; Abdelnabi R; Foo SC; Cameroni E; Stumpf S; Croll TI; Nix JC; Havenar-Daughton C; Piccoli L; Benigni F; Neyts J; Telenti A; Lempp FA; Pizzuto MS; Chodera JD; Hebner CM; Virgin HW; Whelan SPJ; Veesler D; Corti D; Bloom JD; Snell G
    Nature; 2021 Sep; 597(7874):97-102. PubMed ID: 34261126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.
    Yuan TZ; Garg P; Wang L; Willis JR; Kwan E; Hernandez AGL; Tuscano E; Sever EN; Keane E; Soto C; Mucker EM; Fouch ME; Davidson E; Doranz BJ; Kailasan S; Aman MJ; Li H; Hooper JW; Saphire EO; Crowe JE; Liu Q; Axelrod F; Sato AK
    MAbs; 2022; 14(1):2002236. PubMed ID: 34967699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy.
    Xiang Y; Xu J; McGovern BL; Ranzenigo A; Huang W; Sang Z; Shen J; Diaz-Tapia R; Pham ND; Teunissen AJP; Rodriguez ML; Benjamin J; Taylor DJ; van Leent MMT; White KM; García-Sastre A; Zhang P; Shi Y
    Cell; 2024 Nov; 187(24):6966-6980.e23. PubMed ID: 39447570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring distinct modes of inter-spike cross-linking for enhanced neutralization by SARS-CoV-2 antibodies.
    Nan X; Li Y; Zhang R; Wang R; Lv N; Li J; Chen Y; Zhou B; Wang Y; Wang Z; Zhu J; Chen J; Li J; Chen W; Zhang Q; Shi X; Zhao C; Chen C; Liu Z; Zhao Y; Liu D; Wang X; Yan LT; Li T; Zhang L; Yang YR
    Nat Commun; 2024 Dec; 15(1):10578. PubMed ID: 39632831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice.
    Becker W; Rebbani K; Duan Z; Valkov E; Bryant S; Ho M; Berzofsky JA; Olkhanud PB
    Sci Rep; 2024 Nov; 14(1):29609. PubMed ID: 39609527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic study of the transmission pattern of the SARS-CoV-2 omicron variant.
    An K; Yang X; Luo M; Yan J; Xu P; Zhang H; Li Y; Wu S; Warshel A; Bai C
    Proteins; 2024 Jun; 92(6):705-719. PubMed ID: 38183172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.
    Jennewein MF; MacCamy AJ; Akins NR; Feng J; Homad LJ; Hurlburt NK; Seydoux E; Wan YH; Stuart AB; Edara VV; Floyd K; Vanderheiden A; Mascola JR; Doria-Rose N; Wang L; Yang ES; Chu HY; Torres JL; Ozorowski G; Ward AB; Whaley RE; Cohen KW; Pancera M; McElrath MJ; Englund JA; Finzi A; Suthar MS; McGuire AT; Stamatatos L
    Cell Rep; 2021 Jul; 36(2):109353. PubMed ID: 34237283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection.
    Liu H; Yuan M; Huang D; Bangaru S; Zhao F; Lee CD; Peng L; Barman S; Zhu X; Nemazee D; Burton DR; van Gils MJ; Sanders RW; Kornau HC; Reincke SM; Prüss H; Kreye J; Wu NC; Ward AB; Wilson IA
    Cell Host Microbe; 2021 May; 29(5):806-818.e6. PubMed ID: 33894127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An antibody from single human V
    Luo S; Zhang J; Kreutzberger AJB; Eaton A; Edwards RJ; Jing C; Dai HQ; Sempowski GD; Cronin K; Parks R; Ye AY; Mansouri K; Barr M; Pishesha N; Williams AC; Vieira Francisco L; Saminathan A; Peng H; Batra H; Bellusci L; Khurana S; Alam SM; Montefiori DC; Saunders KO; Tian M; Ploegh H; Kirchhausen T; Chen B; Haynes BF; Alt FW
    Sci Immunol; 2022 Oct; 7(76):eadd5446. PubMed ID: 35951767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains.
    Starr TN; Greaney AJ; Stewart CM; Walls AC; Hannon WW; Veesler D; Bloom JD
    PLoS Pathog; 2022 Nov; 18(11):e1010951. PubMed ID: 36399443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.
    Rogers TF; Zhao F; Huang D; Beutler N; Burns A; He WT; Limbo O; Smith C; Song G; Woehl J; Yang L; Abbott RK; Callaghan S; Garcia E; Hurtado J; Parren M; Peng L; Ramirez S; Ricketts J; Ricciardi MJ; Rawlings SA; Wu NC; Yuan M; Smith DM; Nemazee D; Teijaro JR; Voss JE; Wilson IA; Andrabi R; Briney B; Landais E; Sok D; Jardine JG; Burton DR
    Science; 2020 Aug; 369(6506):956-963. PubMed ID: 32540903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.